About Us | About BioTherapeutics

BioTherapeutics, a unit of Baxter’s European Bioscience business, develops and provides innovative therapies to patients and the healthcare community. Every day we aim to provide high quality and effective treatments to help save and sustain the lives of patients in our focused therapeutic areas. BioTherapeutics focuses in 2 key therapeutic areas:

• Immunoglobulins
• Critical care

Immunoglobulins

BioTherapeutics provides a comprehensive portfolio of Ig product for all treatment settings – hospital, outpatient clinic and home. Our immunoglobulin products are used to treat various conditions including, but not limited to,

• Replacement therapy in Primary immunodeficiencies (PID)
• Secondary immunodeficiencies (SID)
• Immune Thrombocytopenic Purpura (ITP)
• Guillain-Barré Syndrome
• Kawasaki disease
• Allogeneic Bone Marrow Transplantation

back to top

Critical Care

BioTherapeutics provide a broad range of critical care therapies to primarily treat:

• Plasma-volume replacement therapy for the treatment of hypovolemia
• Severe congenital Protein C deficiency

back to top